Search results
Showing 421 to 435 of 888 results for community guidance
applicable) Why this is important:- Many people in contact with the community-based criminal justice services have significant mental...
(both urethral and suprapubic) are commonly used in both hospital and community care settings. Long-term catheterisation carries a...
significant differences in mortality or service outcomes, and did not consider community care resources or unpaid...
management of pain in children and young people with cerebral palsy in a community setting? Any explanatory notes(if applicable) Why...
loss:- What is the predictive value of risk tools for identifying people in the community who are atincreased risk of developing chronic...
multiagency working and how GPs can support transitions from hospital to the community for this population.Qualitative studies gauging...
involvement of local community in designing changes- ongoing 'ownership' by local community- management and maintenance....
How we collect and use your personal information, and your rights under data protection legislation.
clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome?...
NG142/3 Question What are the benefits of planned, regular community-based reviews compared with as-required review of non-cancer...
babies showing non-IgE-mediated food allergy symptoms in primary care and community settings? Any explanatory notes(if applicable) Why...
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)
Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.